Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects

Executive Summary

Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.

Advertisement

Related Content

CVS Will Retain $300M In Drug Rebates In 2018, PBM Says
Highest-Cost Drugs Could Feel Biggest Pinch From Part B Step Therapy Policy
Highest-Cost Drugs Could Feel Biggest Pinch From Part B Step Therapy Policy
Medicare Value-Based Contracting, Vendor Price Negotiation To Be Tested In Part B Demo

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel